ID   MDA-MB-231 shWDR12-4
AC   CVCL_YJ26
DR   cancercelllines; CVCL_YJ26
DR   Wikidata; Q95987355
RX   CelloPub=CLPUB00550;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Doubling time: 20-27 hours (CelloPub=CLPUB00550).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
CC   Miscellaneous: Corrections of STR profile from thesis manuscript (CelloPub=CLPUB00550) from personal communication of Al-awar, Rima.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): CelloPub=CLPUB00550; Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 13
ST   D16S539: 12
ST   D21S11: 30,33.2
ST   D5S818: 12
ST   D7S820: 8,9
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0062 ! MDA-MB-231
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 10-09-24; Version: 12
//
RX   CelloPub=CLPUB00550;
RA   Benhamron S.;
RT   "Validating WDR12 as a potential drug target in triple negative breast
RT   cancer.";
RL   Thesis MSc (2019); University of Toronto; Toronto; Canada.
//